{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:15:13Z","timestamp":1787235313757,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T00:00:00Z","timestamp":1633910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T00:00:00Z","timestamp":1633910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Marlyn Fein Chapter of the Fox Chase Cancer Center Board of Associates"},{"DOI":"10.13039\/100007197","name":"United States Public Health Services","doi-asserted-by":"crossref","award":["P30CA006927"],"award-info":[{"award-number":["P30CA006927"]}],"id":[{"id":"10.13039\/100007197","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1245\/s10434-021-10883-5","type":"journal-article","created":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:28:06Z","timestamp":1633998486000},"page":"1683-1691","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Neoadjuvant Endocrine Therapy and Delays in Surgery for Ductal Carcinoma in Situ: Implications for the Coronavirus Pandemic"],"prefix":"10.1245","volume":"29","author":[{"given":"Austin D.","family":"Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elin R.","family":"Sigurdson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Hsiung","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison A.","family":"Aggon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen V.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Porpiglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Bleicher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,11]]},"reference":[{"key":"10883_CR1","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1002\/cncr.20979","volume":"103","author":"LC Collins","year":"2005","unstructured":"Collins LC, Tamimi RM, Baer HJ, Connolly JL, Colditz GA, Schnitt SJ. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy. Cancer. 2005;103:1778\u201384. https:\/\/doi.org\/10.1002\/cncr.20979.","journal-title":"Cancer."},{"key":"10883_CR2","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10549-005-9101-z","volume":"97","author":"B Erbas","year":"2006","unstructured":"Erbas B, Provenzano E, Armes J, Gertig D. The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat. 2006;97:135\u201344. https:\/\/doi.org\/10.1007\/s10549-005-9101-z.","journal-title":"Breast Cancer Res Treat."},{"key":"10883_CR3","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.molonc.2013.07.005","volume":"7","author":"CF Cowell","year":"2013","unstructured":"Cowell CF, Weigelt B, Sakr RA, et al. Progression from ductal carcinoma in situ to invasive breast cancer: revisited. Mol Oncol. 2013;7:859\u201369. https:\/\/doi.org\/10.1016\/j.molonc.2013.07.005.","journal-title":"Mol Oncol."},{"key":"10883_CR4","unstructured":"Abraham J, Aft R, Agnese D, et al. NCCN Guidelines Version 3.2021 Breast Cancer. 2021. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf. Accessed 8 Oct 2021."},{"key":"10883_CR5","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3389\/fonc.2017.00248","volume":"7","author":"KL Gorringe","year":"2017","unstructured":"Gorringe KL, Fox SB. Ductal carcinoma in situ biology, biomarkers, and diagnosis. Front Oncol. 2017;7:248. https:\/\/doi.org\/10.3389\/fonc.2017.00248.","journal-title":"Front Oncol."},{"key":"10883_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/jncimonographs\/lgq027","volume":"2010","author":"K Kerlikowske","year":"2010","unstructured":"Kerlikowske K. Epidemiology of ductal carcinoma in situ. J Natl Cancer Inst Monogr. 2010;2010:139\u201341. https:\/\/doi.org\/10.1093\/jncimonographs\/lgq027.","journal-title":"J Natl Cancer Inst Monogr."},{"key":"10883_CR7","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1056\/NEJMoa1206809","volume":"367","author":"A Bleyer","year":"2012","unstructured":"Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med. 2012;367:1998\u20132005. https:\/\/doi.org\/10.1056\/NEJMoa1206809.","journal-title":"N Engl J Med."},{"key":"10883_CR8","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1146\/annurev-med-050715-104920","volume":"68","author":"AV Barrio","year":"2017","unstructured":"Barrio AV, Van Zee KJ. Controversies in the treatment of ductal carcinoma in situ. Annu Rev Med. 2017;68:197\u2013211. https:\/\/doi.org\/10.1146\/annurev-med-050715-104920.","journal-title":"Annu Rev Med."},{"key":"10883_CR9","unstructured":"LORIS\u2013University of Birmingham. Retrieved 17 April 2021 at https:\/\/www.birmingham.ac.uk\/research\/crctu\/trials\/loris\/index.aspx."},{"key":"10883_CR10","unstructured":"Management of Low-risk (Grade I and II) DCIS - Full Text View - ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02492607. Accessed April 17, 2021."},{"key":"10883_CR11","unstructured":"Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial for Low-Risk DCIS: Full Text View\u2013ClinicalTrials.gov. Retrieved 17 April 2021 at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02926911."},{"issue":"15 suppl","key":"10883_CR12","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1200\/jco.2019.37.15_suppl.tps603","volume":"37","author":"C Kanbayashi","year":"2019","unstructured":"Kanbayashi C, Thompson AM, Hwang E-SS, et al. The international collaboration of active surveillance trials for low-risk DCIS LORIS, LORD, COMET, LORETTA. J Clin Oncol. 2019;37(15 suppl):TPS603\u20134. https:\/\/doi.org\/10.1200\/jco.2019.37.15_suppl.tps603.","journal-title":"J Clin Oncol."},{"key":"10883_CR13","doi-asserted-by":"publisher","first-page":"232","DOI":"10.7150\/jca.2.232","volume":"2","author":"SA Lari","year":"2011","unstructured":"Lari SA, Kuerer HM. Biological markers in DCIS and risk of breast recurrence: a systematic review. J Cancer. 2011;2:232\u201361. https:\/\/doi.org\/10.7150\/jca.2.232.","journal-title":"J Cancer."},{"key":"10883_CR14","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1245\/s10434-019-07844-4","volume":"27","author":"WH Ward","year":"2020","unstructured":"Ward WH, DeMora L, Handorf E, et al. Preoperative delays in the treatment of DCIS and the associated incidence of invasive breast cancer. Ann Surg Oncol. 2020;27:386\u201396. https:\/\/doi.org\/10.1245\/s10434-019-07844-4.","journal-title":"Ann Surg Oncol."},{"key":"10883_CR15","unstructured":"CMS Releases Recommendations on Adult Elective Surgeries, Non-Essential Medical, Surgical, and Dental Procedures During COVID-19 Response\/CMS. Retrieved 17 April 2021 at https:\/\/www.cms.gov\/newsroom\/press-releases\/cms-releases-recommendations-adult-elective-surgeries-non-essential-medical-surgical-and-dental."},{"key":"10883_CR16","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1245\/s10434-020-08461-2","volume":"27","author":"DL Bartlett","year":"2020","unstructured":"Bartlett DL, Howe JR, Chang G, et al. Management of cancer surgery cases during the COVID-19 pandemic: considerations. Ann Surg Oncol. 2020;27:1717\u201320. https:\/\/doi.org\/10.1245\/s10434-020-08461-2.","journal-title":"Ann Surg Oncol."},{"key":"10883_CR17","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s10549-020-05644-z","volume":"181","author":"JR Dietz","year":"2020","unstructured":"Dietz JR, Moran MS, Isakoff SJ, et al. Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic the COVID-19 pandemic breast cancer consortium. Breast Cancer Res Treat. 2020;181:487\u201397. https:\/\/doi.org\/10.1007\/s10549-020-05644-z.","journal-title":"Breast Cancer Res Treat."},{"key":"10883_CR18","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1001\/jamaoncol.2016.6905","volume":"3","author":"DJ Boffa","year":"2017","unstructured":"Boffa DJ, Rosen JE, Mallin K, et al. Using the National Cancer Database for outcomes research: a review. JAMA Oncol. 2017;3:1722\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2016.6905.","journal-title":"JAMA Oncol."},{"key":"10883_CR19","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1245\/s10434-019-07213-1","volume":"26","author":"K Mallin","year":"2019","unstructured":"Mallin K, Browner A, Palis B, et al. Incident cases captured in the National Cancer Database compared with those in US population-based central cancer registries in 2012\u20132014. Ann Surg Oncol. 2019;26:1604\u201312. https:\/\/doi.org\/10.1245\/s10434-019-07213-1.","journal-title":"Ann Surg Oncol."},{"key":"10883_CR20","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1200\/JCO.2010.34.0141","volume":"30","author":"DC Allred","year":"2012","unstructured":"Allred DC, Anderson SJ, Paik S, et al. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol. 2012;30:1268\u201373. https:\/\/doi.org\/10.1200\/JCO.2010.34.0141.","journal-title":"J Clin Oncol."},{"key":"10883_CR21","doi-asserted-by":"publisher","first-page":"933","DOI":"10.2217\/fon.14.266","volume":"11","author":"G Mustacchi","year":"2015","unstructured":"Mustacchi G, Scanni A, Capasso I, Farris A, Pluchinotta A, Isola G. Update of the phase III trial \u201cGRETA\u201d of surgery and tamoxifen versus tamoxifen alone for early breast cancer in elderly women. Future Oncol. 2015;11:933\u201341. https:\/\/doi.org\/10.2217\/fon.14.266.","journal-title":"Future Oncol."},{"key":"10883_CR22","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1002\/bjs.4603","volume":"91","author":"M Fennessy","year":"2004","unstructured":"Fennessy M, Bates T, MacRae K, Riley D, Houghton J, Baum M. Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer. Br J Surg. 2004;91:699\u2013704. https:\/\/doi.org\/10.1002\/bjs.4603.","journal-title":"Br J Surg."},{"key":"10883_CR23","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/1471-2407-9-285","volume":"9","author":"YY Chen","year":"2009","unstructured":"Chen YY, DeVries S, Anderson J, et al. Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ. BMC Cancer. 2009;9:285. https:\/\/doi.org\/10.1186\/1471-2407-9-285.","journal-title":"BMC Cancer."},{"key":"10883_CR24","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1038\/bjc.2013.151","volume":"108","author":"G Allevi","year":"2013","unstructured":"Allevi G, Strina C, Andreis D, et al. Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and\/or progesterone receptor-positive breast cancer. Br J Cancer. 2013;108:1587\u201392. https:\/\/doi.org\/10.1038\/bjc.2013.151.","journal-title":"Br J Cancer."},{"key":"10883_CR25","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s10549-014-2835-8","volume":"144","author":"R Carpenter","year":"2014","unstructured":"Carpenter R, Doughty JC, Cordiner C, et al. Optimum duration of neoadjuvant letrozole to permit breast-conserving surgery. Breast Cancer Res Treat. 2014;144:569\u201376. https:\/\/doi.org\/10.1007\/s10549-014-2835-8.","journal-title":"Breast Cancer Res Treat."},{"key":"10883_CR26","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1001\/jamaoncol.2016.1897","volume":"2","author":"LM Spring","year":"2016","unstructured":"Spring LM, Gupta A, Reynolds KL, et al. Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2:1477\u201386. https:\/\/doi.org\/10.1001\/jamaoncol.2016.1897.","journal-title":"JAMA Oncol."},{"key":"10883_CR27","unstructured":"COVID-19 Pandemic Breast Cancer Consortium Develops Considerations for Re-entry. Retrieved 17 April 2021 at https:\/\/www.facs.org\/quality-programs\/cancer\/news\/considerations-for-reentry-051520."},{"key":"10883_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-026797","volume":"9","author":"ES Hwang","year":"2019","unstructured":"Hwang ES, Hyslop T, Lynch T, et al. The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS). BMJ Open. 2019;9:e026797. https:\/\/doi.org\/10.1136\/bmjopen-2018-026797.","journal-title":"BMJ Open."},{"key":"10883_CR29","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/j.ejca.2015.05.008","volume":"51","author":"LE Elshof","year":"2015","unstructured":"Elshof LE, Tryfonidis K, Slaets L, et al. Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low-risk ductal carcinoma in situ: the LORD study. Eur J Cancer. 2015;51:1497\u2013510. https:\/\/doi.org\/10.1016\/j.ejca.2015.05.008.","journal-title":"Eur J Cancer."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-10883-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-021-10883-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-10883-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T12:05:15Z","timestamp":1643803515000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-021-10883-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,11]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10883"],"URL":"https:\/\/doi.org\/10.1245\/s10434-021-10883-5","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,11]]},"assertion":[{"value":"18 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}